Alphama

AlphaMa is a pioneering drug R&D company based in Suzhou, China, established in 2018. With artificial intelligence (AI) as the driving technology, DNA-encoded library (DEL) technology is cross-applied to establish a cutting-edge Intelligent DEL (iDEL) platform(including the first-class technology of on-demand DEL synthesis, DEL screening, hit confirmation, macrocyclic peptide DELs, customized glue library, etc.). The iDEL platform at AlphaMa features first-class DNA-encoded library (DEL) technology specializing in small molecule, macrocyclic peptide and covalent hit discovery, etc. With its mature screening technology and high success rate, providing global partners with a cost-effective and efficient one-stop DEL screening service. Our flexible service model, diversified services and excellent service system cover all stages of early drug discovery. We provide flexible and cost-effective approaches to meet customers' diverse needs with professional technology and high-quality services. AlphaMa is your ideal partner for drug discovery, assisting you in accelerating the drug discovery process. Reach out to learn more: liuyulin@aiphama.cn